Patents by Inventor Christopher Carosino

Christopher Carosino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD47 Antibodies and Uses Thereof for Treating Cancer
    Publication number: 20220135674
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Application
    Filed: October 20, 2021
    Publication date: May 5, 2022
    Applicant: Seagen Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
  • CD47 antibodies and uses thereof for treating cancer
    Patent number: 11180552
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 23, 2021
    Assignee: Seagen Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
  • CD47 Antibodies and Uses Thereof for Treating Cancer
    Publication number: 20190185561
    Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
    Type: Application
    Filed: November 29, 2018
    Publication date: June 20, 2019
    Applicant: Seattle Genetics, Inc.
    Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus